Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_2
1
50%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution1 total trials
Phase 2Efficacy & side effects
1(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Enrolling by invitation2

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 21 (100.0%)

Trials by Status

enrolling_by_invitation2100%

Recent Activity

0 active trials
Showing 2 of 2
enrolling_by_invitationphase_2

Targeting Neuroinflammation as a Contributing Pathology in Alzheimer's Disease Dementia and Related Dementias

NCT04786223
enrolling_by_invitation

Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders

NCT04680130

Clinical Trials (2)

Showing 2 of 2 trials
NCT04786223Phase 2

Targeting Neuroinflammation as a Contributing Pathology in Alzheimer's Disease Dementia and Related Dementias

Enrolling By Invitation
NCT04680130

Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders

Enrolling By Invitation

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2